Comparative Pharmacokinetic Evaluation of Controlled Release Matrix Tablet of Milnacipran Hydrochloride in Rabbit

ISSN: 2210-304X (Online)
ISSN: 2210-3031 (Print)

Volume 7, 3 Issues, 2017

Download PDF Flyer

Drug Delivery Letters

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Jia-You Fang
Pharmaceutics Laboratory
Graduate Institute of Natural Products
Chang Gung University

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Comparative Pharmacokinetic Evaluation of Controlled Release Matrix Tablet of Milnacipran Hydrochloride in Rabbit

Drug Delivery Letters, 4(1): 21-25.

Author(s): Gautam Singhvi, Abhishek Shah, Sri R. Nalla and Ranendra N Saha.

Affiliation: Department of Pharmacy, Industrial Research Laboratory, Birla Institute of Technology and Science, Pilani, Rajasthan, Pin: 333 031, India.


Milnacipran hydrochloride (MIL) is a selective serotonin and norepinephrine dual reuptake inhibitor used for the treatment of depression and fibromyalgia. The aim of present work was to carry out comparative pharmacokinetics evaluation of in-house developed oral controlled release (CR) and marketed immediate release (IR) tablet formulation of MIL. Three prototype CR formulations (i) MIL with HPMC 100K, single hydrophilic polymeric matrix tablet [MSH], (ii) MIL with HPMC 100K and sodium CMC, binary hydrophilic polymeric matrix tablet [MBH] and (iii) MIL with hydrophilic and hydrophobic wax polymeric matrix tablets using HPMC 100K and paraffin wax [MHW] were formulated. One optimized formulation from each prototype formulation was selected for in-vivo study in rabbits. In-vivo plasma concentration data were obtained from 6 healthy male New Zealand albino rabbits after administration of IR and CR tablets of MIL. Plasma samples were analyzed by in-house developed RP-HPLC method. Remarkable differences in plasma drug profile were observed between IR and CR formulations, expressed by lower Cmax, delayed Tmax and extended MRT values for CR tablets. The mean Cmax and Tmax values from CR tablets were found to be 480.28 ± 31.27 to 586.53 ± 15.24 ng/mL and 8 to 10 h respectively whereas for IR formulation these were 1075.25± 50.38 ng/mL and 1 h respectively. The MRT was found twice in CR formulation than IR formulation. Level A in-vitro and in-vivo correlation was also established for developed CR formulations with correlation coefficient 0.896 to 0.930, which indicates a fair correlation between in-vitro release and in-vivo absorption of MIL from dosage form.


Controlled release, in-vitro, in-vivo, milnacipran, pharmacokinetic.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 4
Issue Number: 1
First Page: 21
Last Page: 25
Page Count: 5
DOI: 10.2174/22103031113036660014

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science